| Literature DB >> 36235656 |
Drake W Lem1, Dennis L Gierhart2, Pinakin Gunvant Davey1.
Abstract
Digital eye strain is a complex, multifactorial condition that can be caused by excessive screen time exposure to various electronic devices such as smartphones, tablets, e-readers, and computers. Current literature suggests oxidative damage concomitant with a chronic pro-inflammatory state represent significant etiopathogenic mechanisms. The present review aims to discuss the potential dietary role for micronutrients with nutraceutical properties to ameliorate various ocular and vision-related symptoms associated with digital eye strain. For ocular surface dysfunction, enhanced anti-inflammatory benefits with omega-3 polyunsaturated fatty acids have been well documented for treatment of dry eye disease. The anti-oxidative and immunosuppressive properties of anthocyanin phytochemicals may also confer protective effects against visually induced cognitive stress and digital asthenopia. Meanwhile, nutraceutical strategies involving xanthophyll macular carotenoids demonstrate enhanced cognitive functioning and overall visual performance that aids digital eye strain. Collectively, preliminary findings seem to offer a strong line of evidence to substantiate the need for additional randomized controlled trials aimed at treating digital eye strain with adjunctive nutraceutical strategies. Further RCT and comparisons on commercially available nutritional supplements are needed to quantify the clinical benefits.Entities:
Keywords: anthocyanins; carotenoids nutraceuticals; computer vision syndrome; digital asthenopia; digital eye strain; dry eye disease; omega-3 polyunsaturated fatty acids; visual display terminal syndrome
Mesh:
Substances:
Year: 2022 PMID: 36235656 PMCID: PMC9570730 DOI: 10.3390/nu14194005
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of the randomized clinical trials using omega-3 PUFA.
| Author (Year) | Participants | Duration | Interventions per Day | Results |
|---|---|---|---|---|
| Bhargava (2015) [ | 478 patients with CVS; aged (23.3 ± 4.7) years in India | 3 months | 360 mg EPA + 240 mg DHA; placebo | Significant improvements in TBUT, Schirmer scores, and DESS scores ( |
| Bhargava (2016) [ | 266 patients with CVS; aged (2±9.4 ± 4.8) years in India | 45 days | 1440 mg EPA + 960 mg DHA; placebo | Significant improvements in TBUT ( |
| Deinema (2017) [ | 54 patients with mild/moderate DE; aged (42.6 ± 3.9) years in Australia | 90 days | 1000 mg EPA + 500 mg DHA (in fish oil); 945 mg EPA + 510 mg DHA (in krill oil); placebo | Marked reduction in tear osmolarity ( |
| Epitropoulos (2016) [ | 105 patients with DE & MGD; aged (56.8 ± 17) years in USA | 12 weeks | 1680 mg EPA + 560 mg DHA; “placebo” (3136 mg linoleic acid) | Statistically significant reduction in tear osmolarity, OSDI scores, and TBUT ( |
| Kangari (2013) [ | 64 patients with DE; aged (61.2 ± 8.3) years in USA | 1 month | 360 mg EPA + 240 mg DHA; placebo | Remarkable improvements in TBUT ( |
| Korb (2015) [ | 26 patients with Evaporative DE; aged (41.7 ± 19.8) years in USA | 3 months | 1000 mg omega-3 PUFA; placebo | Mean OSDI scores improved (+55%) significantly from baseline ( |
| Macsai (2008) [ | 38 patients with MGD; aged (50.7 ± 9.1) years in USA | 12 months | ~3300 mg ALA (in flaxseed oil, 6 g); placebo | Significant improvements in meibum scores ( |
| Malhotra (2015) [ | 60 patients with moderate MGD; aged (53.3 ± 6.9) years in India | 12 weeks | 720 mg EPA + 480 mg DHA; placebo | Enhanced benefits in OSDI scores, TBUT, and CS ( |
| Olenik (2017) [ | 61 patients with MGD; aged (mean 56) years in Spain | 3 months | 1050 mg DHA + 127 mg EPA + 90 mg DPA (1.2 g total); placebo | TBUT, mean OSDI scores, lipid margin inflammation improved significantly ( |
Abbreviations: CVS, computer vision syndrome; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; TBUT, tear break-up time; DESS, dry eye scoring system; DE, dry eye disease; MGD, meibomian gland dysfunction; OSDI, ocular surface disease index; ALA, alpha-linolenic acid; DPA, docosapentaenoic acid.
Characteristics of the randomized clinical trials using anthocyanin nutraceuticals.
| Author (Year) | Participants | Duration | Interventions per Day | VDT-Task | Results |
|---|---|---|---|---|---|
| Kizawa (2021) [ | 44 adults with DES; aged (36.6 ± 9.1) years in Japan | 6 weeks | 200 mg bilberry extract ( | Video game (60 min) | Reversed adverse effect on pupillary response with VDT-task ( |
| Kono (2014) [ | 48 adults with eye strain; aged (52.8 ± 0.9) years in Japan | 4 weeks | 20 mg bilberry extract & 26.5 mg black soybean hull extract ( |
| Improved near-point accommodation variation in both eyes ( |
| Kosehira (2020) [ | 109 adults with heavy VDT use; aged (35.8 ± 7.0) years in Japan | 12 weeks | 240 mg standard bilberry extract; placebo | Video game (40 min) | Relieved tonic accommodation in ciliary muscle triggered by VDT-task ( |
| Ozawa (2017) [ | 88 adults with heavy VDT use; aged (30.7 ± 0.9) years in Japan | 8 weeks | 480 mg bilberry extract; placebo | Video game (60 min) | Marked improvement in CFF ( |
| Park (2016) [ | 60 adults with CVS; aged (38.9 ± 10.6) years in Korea | 4 weeks | 1000 mg bilberry extract; placebo | Watch movie (60 min) | Significant improvement in subjective asthenopic symptoms induced by VDT-task ( |
| Riva (2017) [ | 22 adults with heavy VDT use; aged (45.5 ± 7.3) years in Italy | 4 weeks | 160 mg Mirtoselect® standard bilberry extract (≥36% anthocyanins); placebo | Video game (45 min) | Statistically significant improvement in Schirmer’s test score ( |
| Rossi (2021) [ | 30 adults with heavy VDT use; aged (44.9 ± 9.1) years in Italy | 1 month | 300 mg elderberry & 100 mg black currant extracts ( |
| Remarkable improvements in CVSS questionnaire scores and contrast sensitivity at higher spatial frequencies ( |
| Sekikawa (2021) [ | 32 healthy adults with DES; aged (37.1 ± 8.4) years in Japan | 6 weeks | 43.2 mg bilberry extract; placebo | Video game (60 min) | Protective effect against accommodative function decline with VDT-task ( |
| Yamashita (2019) [ | 74 adults with DES; aged (44.8 ± 7.4) years in Japan | 4 weeks | 60 mg MaquiBright® SMBE (≥35% anthocyanins); placebo | Video game (45 min) | Significant improvements in Schirmer’s test ( |
Abbreviations: DES, digital eye strain; VDT, visual display terminal; CFF, critical flicker fusion; CVSS, computer vision symptom scale; DES, digital eye strain; SMBE, standard maqui berry extract; VAS, visual analogue scale; DEQS, dry eye-related quality of life score.
Characteristics of the randomized clinical trials using carotenoids.
| Author (Year) | Participants | Duration | No. of Groups | Interventions per Day | Results |
|---|---|---|---|---|---|
| Kan (2020) [ | 360 adults with DES; aged (38.3 ± 8.3) years in China | 90 days | 4 | 12 mg L + 1.2 mg Z; 20 mg L + 2 mg Z; 28 mg L + 2.8 mg Z; placebo | Significant improvement in TBUT, Schirmer’s test, and eye fatigue symptoms ( |
| Kawabata (2011) [ | 20 adults with heavy VDT use; aged (25.2 ± 1.2) years in Japan | 4 weeks | 2 | 17.5 mg L ( | Safely improved subjective complaints of asthenopia and mental fatigue from VDTs |
| Kizawa (2021) [ | 44 adults with DES; aged (36.6 ± 9.1) years in Japan | 6 weeks | 2 | 5 mg L + 3 mg Ax ( | Ameliorated reduction in accommodative function and visual performance (both |
| Kono (2014) [ | 48 adults with eye strain; aged (52.8 ± 0.9) years in Japan | 4 weeks | 2 | 10 mg L + 4 mg Ax ( | Protection against accommodative amplitude decline from VDT use ( |
| Ma (2009) [ | 37 adults with DES; aged (24.8 ± 2.0) years in China | 12 weeks | 3 | 6 mg L; 12 mg L; placebo | Higher intake of lutein may offer enhanced benefit in visual performance measures |
| Nagaki (2002) [ | 26 adults with VDT use; aged (47.7 ± 4.4) years in Japan | 4 weeks | 2 | 5 mg Ax; placebo | Marked increase in accommodative amplitude ( |
| Stringham (2016) [ | 59 healthy young adults; aged (21.7 ± 1.0) years in USA | 12 months | 3 | 10 mg L + 1 mg Z + 1 mg MZ; 20 mg L + 2 mg Z + 2 mg MZ; placebo | Significant increase in MPOD resulted in improved PSR and DG ( |
| Stringham (2017) [ | 48 healthy adults with +6 h/day screen time; aged (21.2) years in USA | 6 months | 2 | 20 mg L + 2.5 mg Z + 1.5 mg MZ; placebo | MPOD increased significantly along with enhanced visual performance measures and sleep quality ( |
| Stringham (2018) [ | 59 healthy young adults; aged (21.5) years in USA | 12 months | 3 | 10.86 mg L + 2.27 mg Z-MZ isomers; 22.3 mg L + 4.7 Z-MZ isomers; placebo | Statistically significant relationship between increased MPOD and reductions in serum cortisol ( |
Abbreviations: DES, digital eye strain; L, lutein; Z, zeaxanthin; TBUT, tear break-up time; VDT, visual display terminal; Ax, astaxanthin; MZ, meso-zeaxanthin; MPOD, macular pigment optical density; PSR, photostress recovery; DG, disability glare.